JF
RAPP

Jump Financial’s Rapport Therapeutics RAPP Stock Holding History

Jump Financial’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,760
Closed -$138K – 2248
2025
Q1 		$138K Buy
+13,760
New +$179K ﹤0.01% 1479

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jump Financial's RAPP Position: Q2 2025 in Review

Jump Financial sold out of Rapport Therapeutics (RAPP) in Q2 2025, closing a stake of 13,760 shares — an estimated $138K sold.

Jump Financial first reported a position in RAPP in Q1 2025 and held it in 1 quarter. The position peaked at $138K in Q1 2025. 82 funds tracked by Wall St. Rank hold RAPP as of Q2 2025.

  • Jump Financial reported no remaining Rapport Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Jump Financial sold 13,760 Rapport Therapeutics shares in Q2 2025, an estimated $138K.
  • Jump Financial first reported a position in Rapport Therapeutics in Q1 2025 and held it in 1 quarter.
  • Jump Financial's Rapport Therapeutics position peaked at $138K in Q1 2025.
  • 82 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2025.

Based on Jump Financial's 13F filing for Q2 2025, filed 13 Aug 2025.